FDMDF
Price:
$0.2279
Market Cap:
$144.18M
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
Industry
Medical - Devices
IPO Date
2021-02-02
Stock Exchange
PNK
Ticker
FDMDF
According to 4DMedical Limited’s latest financial reports and current stock price. The company's current ROE is -60.46%. This represents a change of 143.86% compared to the average of -24.79% of the last 4 quarters.
The mean historical ROE of 4DMedical Limited over the last ten years is -45.77%. The current -60.46% ROE has changed 32.10% with respect to the historical average. Over the past ten years (40 quarters), FDMDF's ROE was at its highest in in the June 2020 quarter at 142.47%. The ROE was at its lowest in in the December 2019 quarter at -254.32%.
Average
-45.77%
Median
-47.38%
Minimum
-142.48%
Maximum
186.08%
Discovering the peaks and valleys of 4DMedical Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 233.27%
Maximum Annual ROE = 186.08%
Minimum Annual Increase = -230.60%
Minimum Annual ROE = -142.48%
Year | ROE | Change |
---|---|---|
2024 | -50.73% | 15.22% |
2023 | -44.02% | 6.53% |
2022 | -41.32% | 60.81% |
2021 | -25.70% | -113.81% |
2020 | 186.08% | -230.60% |
2019 | -142.48% | 36.74% |
2018 | -104.20% | -14.79% |
2017 | -122.29% | 40.66% |
2015 | -86.94% | 233.27% |
The current ROE of 4DMedical Limited (FDMDF) is greater than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-45.36%
5-year avg
4.86%
10-year avg
-45.77%
4DMedical Limited’s ROE is greater than MaxCyte, Inc. (-18.94%), greater than Sight Sciences, Inc. (-52.38%), greater than CVRx, Inc. (-93.06%), greater than NeuroPace, Inc. (-258.10%), greater than Rapid Micro Biosystems, Inc. (-52.06%),
Company | ROE | Market cap |
---|---|---|
-18.94% | $302.46M | |
-52.38% | $156.64M | |
-93.06% | $185.92M | |
-258.10% | $387.46M | |
-52.06% | $102.99M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like 4DMedical Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like 4DMedical Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is 4DMedical Limited's ROE?
How is the ROE calculated for 4DMedical Limited (FDMDF)?
What is the highest ROE for 4DMedical Limited (FDMDF)?
What is the 3-year average ROE for 4DMedical Limited (FDMDF)?
What is the 5-year average ROE for 4DMedical Limited (FDMDF)?
How does the current ROE for 4DMedical Limited (FDMDF) compare to its historical average?